Amylyx Pharmaceuticals (AMLX) Other Non Operating Income (2021 - 2026)
Amylyx Pharmaceuticals' (AMLX) quarterly Other Non Operating Income came in at -$75000.0 in Q1 2026, up 77.61% year-on-year from -$42226.9 in Q1 2025, and down 107.06% quarter-over-quarter from $1.1 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Other Non Operating Income (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Other Non Operating Income history runs 6 years deep, the most recent figure standing at -$75000.0 for Q1 2026.
- On a quarterly basis, Other Non Operating Income rose 77.61% year-over-year to -$75000.0 in Q1 2026; TTM through Mar 2026 was $261000.0, a 132.54% increase from a year earlier, with the FY2024 full-year figure at -$1.2 million, down 83.94% from the prior year.
- Other Non Operating Income retreated to -$75000.0 in Q1 2026 per AMLX's latest filing, from $1.1 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.1 million in Q4 2025 and bottomed at -$747000.0 in Q1 2024.
- The 5-year median for Other Non Operating Income is -$141000.0 (2024), against an average of -$147000.0.
- Across the five-year window, Other Non Operating Income tumbled 1278.95% in 2023 and jumped 576.43% in 2025, its largest moves.
- Year by year, Other Non Operating Income stood at -$689000.0 in 2022, then jumped by 124.82% to $171000.0 in 2023, then fell by 8.19% to $157000.0 in 2024, then soared by 576.43% to $1.1 million in 2025, then sank by 107.06% to -$75000.0 in 2026.
- Per Business Quant, the three latest AMLX Other Non Operating Income figures stand at -$75000.0 (Q1 2026), $1.1 million (Q4 2025), and -$180000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Amylyx Pharmaceuticals | 1.94 Bn | 1.94 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -75,000.00 |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | -180,000.00 |
| Jun 30, 2025 | -546,000.00 |
| Mar 31, 2025 | -335,000.00 |
| Dec 31, 2024 | 157,000.00 |
| Sep 30, 2024 | -141,000.00 |
| Jun 30, 2024 | -483,000.00 |
| Mar 31, 2024 | -747,000.00 |
| Dec 31, 2023 | 171,000.00 |
| Sep 30, 2023 | -488,000.00 |
| Jun 30, 2023 | -81,000.00 |
| Mar 31, 2023 | -262,000.00 |
| Dec 31, 2022 | -689,000.00 |
| Sep 30, 2022 | 199,000.00 |
| Jun 30, 2022 | -42,000.00 |
| Mar 31, 2022 | -19,000.00 |
| Dec 31, 2021 | -59,000.00 |
| Sep 30, 2021 | -227,000.00 |
| Jun 30, 2021 | -26,000.00 |